pegylated interferon/telbivudine sequential therapy in hbe antigen negative severe chronic hepatitis b patient

hepatitis b e antigen-negative chronic hepatitis b

Hepatitis B surface antigen seroconversion in HBeAg negative chronic hepatitis B patient during entecavir treatment.

Chronic hepatitis B (CHB) infection is still a huge public health problem despite the development of new drugs for its treatment, and complications of end-stage liver disease due to this infection results in one million deaths worldwide annually (1). The ideal end-point of therapy is hepatitis B surface antigen (HBsAg) loss with or without HBs seroconversion. However, it is frequently not achie...

Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.

Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.

Role of Hepatitis B Virus Surface Antigen Quantification in E Antigen Negative Chronic Hepatitis B Infection

Background/Aim: Hepatitis B surface antigen(HBsAg) is routinely detected qualitatively in Hepatitis B Virus(HBV) infection where its persistence beyond 6 months defines chronic hepatitis B(CHB) infection. Hepatitis B e antigen (HBeAg) usually indicates active HBV replication and risk of transmission of infection. In spite of the emerging use of chemiluminescence based quantitative HBsAg assays ...

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B

BACKGROUND We investigated the differences in HBsAg kinetics at different levels of viremia in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). METHODS We compared HBsAg levels among HBeAg-negative CHB patients with persistently undetectable HBV DNA (≤20 IU/mL; Group A, n = 100), HBV DNA 20-2,000 IU/mL (Group B, n = 100), and HBV DNA >2,000 IU/mL (Group C, n = 100). HBsAg and...

Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.

BACKGROUND Kinetics of serum hepatitis B surface antigen (HBsAg) level in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients presented with severe reactivation and received oral antiviral therapy is unknown. We aimed to investigate the kinetics of HBsAg level among these patients. METHODS HBeAg-negative patients on antiviral therapy with follow-up for 2 years were studied. Th...